Ascendis Pharma A/S presented updates on its business and product portfolio at the 44th Annual J.P. Morgan Healthcare Conference. The company reported preliminary product revenue of approximately €240 million for the fourth quarter of 2025 and around €683 million for the full year 2025. Its endocrinology rare disease medicines include YORVIPATH® for adult hypoparathyroidism, SKYTROFA® for pediatric and adult growth hormone deficiency, and TransCon® CNP, which is under FDA review with a PDUFA date of February 28, 2026. Ascendis Pharma is expanding commercial launches for its products across more than 30 countries and plans further expansion by the end of 2026. The company is also advancing its TransCon technology platform and pursuing additional opportunities in areas such as ophthalmology, obesity, metabolic diseases, and oncology. Ascendis targets blockbuster status for multiple products and aims to achieve over €5 billion in annual revenue by 2030. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief on January 09, 2026, and is solely responsible for the information contained therein.
